1. Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem.
1955;215:1-14.
2. Brunzell JD. Familial lipoprotein lipase deficiency and others causes of the chylomicronemia syndrome. In; Scriver CR, Beaudet AL, Sly WS, Valle D.
The metabolic basis of inherited disease. New York: McGraw Hill; 1995: p.
1913-32.
3. Miller AL, Smith LC. Activation of lipoprotein lipase by apolipoprotein glutamic acid. Formation of a stable surface film. J Biol Chem. 1973;248:3359-62.
4. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T.
Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry. 1973;12:1828-33.
5. Brown, WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Bioch Biophys Res Com. 1972;46:1265- 73.
6. Borba EF, Bonfá E, Vinagre CGC, Ramires JAF, Maranhão RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1033-40.
7. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M.
Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2957-63.
8. Maury CPJ, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum. 1989;32:146-50.
9. Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Ero S, et al. Production of B cell-stimulating factors by B cells in patients of systemic lupus erythematosus. J Immunol. 1988;141:3043-9.
10. Spronk PE, Ter Borg EJ, Limburg PC, Kallenberg CGM. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992;90:106-10.
11. Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL.
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982;25:396-400.
12. Morrow WJW, Isenberg DA, Parry HF, Snaith ML. C-reactive protein in sera from patients with systemic lupus erythematosus. J Rheumatol. 1981;8:599- 604
13. Pepys MB, Lanham JG, deBeer FC. C-reactive protein in SLE. Clin Rheum Dis. 1982;8:91-103.
14. Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus:
influence of disease, activity, and anticardiolipin antibodies. Lupus.
1997;6:533-9
15. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995;22:1259-64.
16. Stein Y, Stein O. Lipoprotein lipase and atherosclerosis. Atherosclerosis.
2003;170:1-9.
17. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
18. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97
19. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al.
Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ. 2000;321:199-204.
20. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al.
Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-7.
21. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem. 1987;262:8390-4.
22. Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol. 1985;135:3969-71.
23. Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K. Effect of interferon on plasma lipoproteins and on the activity of postheparin lipases. Arteriosclerosis. 1982;2:69-73.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al.
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
25. Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the classification of systemic lupus erythematosus [letter].
Arthritis Rheum. 1997;40:1725.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40.
27. Kurata N, Tan EM. Identification of antibody to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum. 1976;19:574-80.
28. Elkon KB, Culhane L. Partial immunochemical characterization of the Ro and La proteins using antibodies from patients with the sicca syndrome and lupus erythematosus. J Immunol. 1984;132:2350-6.
29. Tan EM, Peebles C. Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination. In: Rose NR, Friedman H; editors.
Manual of clinical immunology. 2nd ed. Washington: Amer Soc
30. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 1987;46:1-6.
31. Siedel J, Hägele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem.1983;29:1075-80.
32. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077-80.
33. Warnick GR, Cheung NC, Albers JJ. Comparison of current methods for high density lipoprotein cholesterol quantification. Clin Chem. 1979;25:596- 604.
34. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
35. Okamoto Y, Tominaga K, Uemura S, Matsuoka H, Tsujii T, Nakano H.
Hypertriglyceridemia caused by the autoantibody to lipases for plasma
36. Yoshimura T, Ito M, Sakoda Y, Kobori S, Okamura H. Rare cases of autoimmune hyperchylomicronemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1998;76:49-51.
37. Pruneta V, Moulin P, Labrousse F, Bondon PJ, Ponsin G, Berthezene F.
Characterization of a new case of autoimmune type I hyperlipidemia: long- term remission under immunosuppressive therapy. J Clin Endocrinol Metabol. 1997;82:791-6
38. Eckel RH. Lipoprotein lipase. A multifuncional enzyme relevant to common metabolic diseases. N Engl J Med. 1989;320:1060-8.
39. Vilella E, Joven J, Fernández M, Vilaro S, Brunzell JD, Olivecrona T, et al.
Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res. 1993;34:1555-64.
40. Clee SM, Bissada N, Miao L, Marais AD, Henderson HE, Steures P, et al.
Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res. 2000;41:521-31.
41. Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in
42. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48:2533-40.
43. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9.
44. Ward MM, Pisetsky DS, Christenson VD. Anti-double stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements. J Rheumatol. 1989;16:609-13.
45. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother.
2003;57:282-6.
46. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99:1997-
47. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Ticani A, et al.
Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun. 2000;15:237-40.
48. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998;98:1108-15.
49. Baumann H, Gauldie J. The acute phase response. Immunol Today.
1994;2:74-80.
50. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C- reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.
51. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C- reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-92.
